Lamzede

Velmanase alfa, the active ingredient in Lamzede, is an enzyme replacement therapy presented as a solution for injection for intravenous use. It replaces deficient lysosomal alpha‑mannosidase activity, addressing the accumulation of mannose‑rich oligosaccharides in patients with alpha‑mannosidosis, a rare inherited lysosomal storage disorder. The product is authorized in the European Union and is administered under medical supervision.

GNH USA supplies Lamzede as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, specialty clinics and procurement teams worldwide, ensuring quality and regulatory compliance across all markets.

Lamzede (velmanase alfa) is an enzyme replacement therapy used in the management of lysosomal storage disorders, specifically alpha‑mannosidosis.

Alpha‑mannosidosis: provides the missing alpha‑mannosidase enzyme, reducing substrate accumulation and improving clinical outcomes.

Velmanase alfa may be associated with a range of adverse reactions observed in clinical use.

Common Side Effects: - Infusion‑related reactions (e.g., flushing, rash, itching) - Headache - Nausea - Fever or chills - Fatigue - Mild abdominal discomfort

Serious or Rare Side Effects: - Anaphylaxis or severe hypersensitivity - Thrombosis or embolic events - Significant hepatic enzyme elevation - Renal impairment or acute kidney injury - Immune complex disease - Severe infusion reactions requiring medical intervention

Prior to initiating therapy, clinicians should consider several safety measures.

Monitoring: Observe patients during and after infusion for signs of hypersensitivity. Renal function: Assess baseline renal parameters before therapy. Hepatic function: Monitor liver enzymes periodically. Pregnancy: Use only if potential benefit justifies potential risk; data are limited. Store at 2-8°C: Keep refrigerated, protect from light, do not freeze or shake.

Velmanase alfa may interact with other medicines; awareness of potential interactions is important.

Major Interactions (Avoid): - Live vaccines: concurrent administration may reduce vaccine efficacy. - Concomitant enzyme therapies: may increase risk of immune reactions. - Immunosuppressants: may alter drug clearance.

Moderate Interactions (Monitor Closely): - Antipyretics: may mask infusion reactions. - Anticoagulants: monitor for bleeding if infusion causes thrombocytopenia. - Corticosteroids: may affect immune response.